Athebio AG

Drumroll, please – curtain up for our webpage’s new look: 🎉🎉🎉 www.athebio.com 🎉🎉🎉 ➡️ Check out the 'About Us' section with amazing new photos of the whole team 😊 (https://lnkd.in/e-Axcuty)   A heartfelt thank you to the people that made this possible for us: Tobias Hohenauer for the illustrations, Michael Koch for layout and release, and Adrian Hyde for the most recent pictures 😊 #DARPin #Athebio #TargetedDelivery with #DARPins

Good morning, Rome! Good morning, #ESGCT24. Looking forward to inspiring talks, posters, and discussions at the 31st Annual Congress of the European Society of Gene and Cell Therapy 😊 There’s so much room for #innovation in this space – so much potential to build on the #Athebody #DARPin platform to help create superior #TargetedTherapeutics with advanced efficacy and safety! My CEO, Thomas Huber, and I are excited to reconnect, listen, and learn. So see you around! #ESGCT2024 #genetherapy #AAV Athebio AG #DARPins

Attending the #festivalofbiologics in Basel this week? Then don’t miss the energizing talk by our CEO Thomas Huber, tomorrow, 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆, 𝟱:𝟭𝟬 𝗽𝗺 𝗶𝗻 𝗧𝗵𝗲𝗮𝘁𝗲𝗿 𝟱, to get an update on #Athebio’s Athebody #DARPin platform aimed to unlock precision of biotherapeutics and enable new biology 🚀   #festofbiologics   #DARPins   #TargetedTherapeutics

Attending the #festivalofbiologics in Basel this week? Then don’t miss the energizing talk by our CEO Thomas Huber, tomorrow, 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆, 𝟱:𝟭𝟬 𝗽𝗺 𝗶𝗻 𝗧𝗵𝗲𝗮𝘁𝗲𝗿 𝟱, to get an update on #Athebio’s Athebody #DARPin platform aimed to unlock precision of biotherapeutics and enable new biology 🚀   #festofbiologics   #DARPins   #TargetedTherapeutics

“Humans did not learn to fly by modifying 𝚋𝚒𝚛𝚍𝚜, instead, 𝚜𝚌𝚒𝚎𝚗𝚝𝚒𝚜𝚝𝚜, inspired by birds, discovered the principles of aerodynamics, 𝚎𝚗𝚐𝚒𝚗𝚎𝚎𝚛𝚜  then used this principles to design custom flying machines” (David Baker) Huge congratulations and thank you to David Baker, Demis Hassabis, and John Jumper for being awarded The Nobel Prize in Chemistry 2024, and kudos to the teams that supported them in achieving this well-deserved honor. The 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗱𝗲𝘀𝗶𝗴𝗻 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻, which pioneered methods to design proteins and catalyzed the prediction of their three-dimensional structures, was initiated by David Baker. Importantly, these methods and tools have always been made freely accessible in an 𝗼𝗽𝗲𝗻, 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁, which also fuels the innovative power of our work at #Athebio. The efficient design principles behind the #DARPin scaffold showcase how tailored proteins can be engineered for specific functions, aligning with David Baker's vision of creating novel proteins with precision and versatility. The Nobel Prize in Chemistry 2024 - NobelPrize.org

🎉Athebio is celebrating its 5th anniversary and treating itself to a new look🎉 Our partners are already in the know, and now we want to show everyone what Tobias from life[science]graphics has created for us to give #Athebio a new logo 😊 Thank you to our talented team putting in all their creativity, passion and heart, and to our exceptional collaboration partners 3T Biosciences, REGENXBIO, Acuitas Therapeutics, Inc. and POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, for their unwavering dedication and excellence in joining us on our mission to unlock precision for targeted therapies! 🚀 #DARPins  #drugdiscovery  #TargetedDelivery

🎉Athebio is celebrating its 5th anniversary and treating itself to a new look🎉 Our partners are already in the know, and now we want to show everyone what Tobias from life[science]graphics has created for us to give #Athebio a new logo 😊 Thank you to our talented team putting in all their creativity, passion and heart, and to our exceptional collaboration partners 3T Biosciences, REGENXBIO, Acuitas Therapeutics, Inc. and POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, for their unwavering dedication and excellence in joining us on our mission to unlock precision for targeted therapies! 🚀 #DARPins  #drugdiscovery  #TargetedDelivery

🎉 One week until it’s time for the Festival of Biologics in Basel, again 🎉 Richard Woods, Christian Jost and Thomas Huber are excited to meet you and discuss how our #Athebody technology platform can boost your #drugdevelopment to unlock 𝗻𝗼𝘃𝗲𝗹 𝗯𝗶𝗼𝗹𝗼𝗴𝘆. ➡️ looking for solutions to your #drugdiscovery needs? ➡️ looking for a partner giving broad access to the Athebody #DARPin technology? 𝗟𝗲𝘁’𝘀 𝗵𝗮𝘃𝗲 𝗮 𝗰𝗵𝗮𝘁! 🚀 #festofbiologics   #DARPins    #festivalofbiologics       

🎉 One week until it’s time for the Festival of Biologics in Basel, again 🎉 Richard Woods, Christian Jost and Thomas Huber are excited to meet you and discuss how our #Athebody technology platform can boost your #drugdevelopment to unlock 𝗻𝗼𝘃𝗲𝗹 𝗯𝗶𝗼𝗹𝗼𝗴𝘆. ➡️ looking for solutions to your #drugdiscovery needs? ➡️ looking for a partner giving broad access to the Athebody #DARPin technology? 𝗟𝗲𝘁’𝘀 𝗵𝗮𝘃𝗲 𝗮 𝗰𝗵𝗮𝘁! 🚀 #festofbiologics   #DARPins    #festivalofbiologics       

Can your body produce its own therapeutics? In principle, yes! Even in cancer immunotherapy with its very complex drugs! “𝗖𝗔𝗥-𝗧”  turns into  “𝗶𝗻 𝘀𝗶𝘁𝘂 𝗖𝗔𝗥-𝗧”. 𝗧 𝗰𝗲𝗹𝗹 𝗲𝗻𝗴𝗮𝗴𝗲𝗿𝘀 (𝗧𝗖𝗘𝘀)  become  𝗶𝗻 𝘀𝗶𝘁𝘂 𝗧𝗖𝗘𝘀 😊 For TCEs, this clearly demands constructs w/o domain mispairing to ensure homogeneity of the therapeutic and safe administration. Local expression of TCEs is attractive to ➡️ enhance tumor site accumulation (= higher efficacy), and to ➡️ reduce systemic concentrations (= higher safety). A collaboration between the University of Zurich and University Hospital Basel is advancing this technology through the use of #DARPin-#scFv fusion proteins that offer 𝗵𝗶𝗴𝗵 𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝗶𝘁𝘆 and 𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 to improve efficacy. (https://lnkd.in/e_h4p2SK) This strategy has demonstrated ➡️ 𝗿𝗲𝗺𝗮𝗿𝗸𝗮𝗯𝗹𝗲 𝘁𝘂𝗺𝗼𝗿 𝗿𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻 and ➡️ 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝗱 𝗧 𝗰𝗲𝗹𝗹 𝗶𝗻𝗳𝗶𝗹𝘁𝗿𝗮𝘁𝗶𝗼𝗻, offering a potent alternative for resistant cancers. #CART #Tcellengager   #DARPins #drugdiscovery #Athebio